AU2014353087B2 - Anti-cancer agents and preparation thereof - Google Patents
Anti-cancer agents and preparation thereof Download PDFInfo
- Publication number
- AU2014353087B2 AU2014353087B2 AU2014353087A AU2014353087A AU2014353087B2 AU 2014353087 B2 AU2014353087 B2 AU 2014353087B2 AU 2014353087 A AU2014353087 A AU 2014353087A AU 2014353087 A AU2014353087 A AU 2014353087A AU 2014353087 B2 AU2014353087 B2 AU 2014353087B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- group
- compound
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XKSGIJNRMWHQIQ-QMBHYHMZSA-N C[C@@H](/C=C\C(N[C@@H]1[C@@H](C)O[C@@H](C/C=C(\C)/C=C/[C@H]([C@H]([C@]2(C3)OC2)O)O[C@]3(C)OC)[C@@H](C)C1)=O)OC(C)=O Chemical compound C[C@@H](/C=C\C(N[C@@H]1[C@@H](C)O[C@@H](C/C=C(\C)/C=C/[C@H]([C@H]([C@]2(C3)OC2)O)O[C@]3(C)OC)[C@@H](C)C1)=O)OC(C)=O XKSGIJNRMWHQIQ-QMBHYHMZSA-N 0.000 description 3
- PJKVJJDQXZARCA-AFNQWATMSA-N C[C@@H](/C=C\C(N[C@@H]1[C@@H](C)O[C@@H](C/C=C(\C)/C=C/[C@H]([C@H]([C@]2(C3)OC2)O)O[C@]3(C)O)[C@@H](C)C1)=O)OC(C)=O Chemical compound C[C@@H](/C=C\C(N[C@@H]1[C@@H](C)O[C@@H](C/C=C(\C)/C=C/[C@H]([C@H]([C@]2(C3)OC2)O)O[C@]3(C)O)[C@@H](C)C1)=O)OC(C)=O PJKVJJDQXZARCA-AFNQWATMSA-N 0.000 description 2
- PJKVJJDQXZARCA-XTFYJZPLSA-N C[C@@H](/C=C\C(N[C@H]1[C@@H](C)O[C@@H](C/C=C(\C)/C=C/[C@H]([C@@H]([C@@]2(C3)OC2)O)O[C@]3(C)O)[C@@H](C)C1)=O)OC(C)=O Chemical compound C[C@@H](/C=C\C(N[C@H]1[C@@H](C)O[C@@H](C/C=C(\C)/C=C/[C@H]([C@@H]([C@@]2(C3)OC2)O)O[C@]3(C)O)[C@@H](C)C1)=O)OC(C)=O PJKVJJDQXZARCA-XTFYJZPLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906133P | 2013-11-19 | 2013-11-19 | |
| US61/906,133 | 2013-11-19 | ||
| PCT/US2014/066458 WO2015077370A1 (en) | 2013-11-19 | 2014-11-19 | Anti-cancer agents and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014353087A1 AU2014353087A1 (en) | 2016-06-30 |
| AU2014353087B2 true AU2014353087B2 (en) | 2018-07-19 |
Family
ID=53180106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014353087A Active AU2014353087B2 (en) | 2013-11-19 | 2014-11-19 | Anti-cancer agents and preparation thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10000505B2 (OSRAM) |
| EP (1) | EP3071563B1 (OSRAM) |
| JP (2) | JP6937578B2 (OSRAM) |
| KR (1) | KR102428737B1 (OSRAM) |
| CN (3) | CN113773333A (OSRAM) |
| AU (1) | AU2014353087B2 (OSRAM) |
| BR (1) | BR112016011430B1 (OSRAM) |
| CA (1) | CA2931111C (OSRAM) |
| CL (1) | CL2016001209A1 (OSRAM) |
| DK (1) | DK3071563T3 (OSRAM) |
| EA (1) | EA035262B1 (OSRAM) |
| ES (1) | ES2943711T3 (OSRAM) |
| FI (1) | FI3071563T3 (OSRAM) |
| IL (2) | IL282430B2 (OSRAM) |
| MX (1) | MX375896B (OSRAM) |
| MY (1) | MY189459A (OSRAM) |
| PE (1) | PE20161240A1 (OSRAM) |
| PH (2) | PH12021551085A1 (OSRAM) |
| PT (1) | PT3071563T (OSRAM) |
| WO (1) | WO2015077370A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3071563B1 (en) * | 2013-11-19 | 2023-04-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| US11584754B2 (en) | 2016-06-08 | 2023-02-21 | William Marsh Rice University | Derivatives of thailanstatin A, methods of treatment and methods of synthesis thereof |
| RU2019111768A (ru) | 2016-09-23 | 2020-10-23 | Пердью Ресерч Фаундейшн | Противораковые агенты и их получение |
| US10301319B2 (en) | 2017-09-20 | 2019-05-28 | Ph Pharma Co., Ltd. | Thailanstatin analogs |
| CN109020876A (zh) * | 2018-09-21 | 2018-12-18 | 大连理工大学 | 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法 |
| PE20211473A1 (es) | 2018-12-13 | 2021-08-05 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso |
| EP4132934A1 (en) * | 2020-04-09 | 2023-02-15 | Bristol-Myers Squibb Company | Meayamycin analogues and methods of use |
| CN113563361B (zh) * | 2021-08-17 | 2022-05-20 | 浙江珲达生物科技有限公司 | 一种从伯克霍尔德菌发酵液提取fr901464的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8309599B2 (en) * | 2006-09-08 | 2012-11-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| WO2013032693A2 (en) * | 2011-08-27 | 2013-03-07 | Marrone Bio Innovations, Inc. | Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom-formulations and uses |
| WO2014068443A1 (en) * | 2012-11-05 | 2014-05-08 | Pfizer Inc. | Spliceostatin analogs |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| NZ587706A (en) | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| AR080234A1 (es) * | 2010-02-25 | 2012-03-21 | Marrone Bio Innovations Inc | Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo |
| EP3071563B1 (en) | 2013-11-19 | 2023-04-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2014
- 2014-11-19 EP EP14863201.1A patent/EP3071563B1/en active Active
- 2014-11-19 PT PT148632011T patent/PT3071563T/pt unknown
- 2014-11-19 MY MYPI2016000932A patent/MY189459A/en unknown
- 2014-11-19 CN CN202110798234.5A patent/CN113773333A/zh active Pending
- 2014-11-19 PH PH1/2021/551085A patent/PH12021551085A1/en unknown
- 2014-11-19 MX MX2016006591A patent/MX375896B/es active IP Right Grant
- 2014-11-19 CN CN202110798232.6A patent/CN113461705A/zh active Pending
- 2014-11-19 KR KR1020167016232A patent/KR102428737B1/ko active Active
- 2014-11-19 CA CA2931111A patent/CA2931111C/en active Active
- 2014-11-19 DK DK14863201.1T patent/DK3071563T3/da active
- 2014-11-19 JP JP2016532025A patent/JP6937578B2/ja active Active
- 2014-11-19 ES ES14863201T patent/ES2943711T3/es active Active
- 2014-11-19 CN CN201480070416.9A patent/CN105829299A/zh active Pending
- 2014-11-19 BR BR112016011430-2A patent/BR112016011430B1/pt active IP Right Grant
- 2014-11-19 US US15/038,027 patent/US10000505B2/en active Active
- 2014-11-19 IL IL282430A patent/IL282430B2/en unknown
- 2014-11-19 WO PCT/US2014/066458 patent/WO2015077370A1/en not_active Ceased
- 2014-11-19 FI FIEP14863201.1T patent/FI3071563T3/fi active
- 2014-11-19 PE PE2016000653A patent/PE20161240A1/es unknown
- 2014-11-19 EA EA201691010A patent/EA035262B1/ru not_active IP Right Cessation
- 2014-11-19 AU AU2014353087A patent/AU2014353087B2/en active Active
-
2016
- 2016-05-15 IL IL245637A patent/IL245637B/en active IP Right Grant
- 2016-05-19 PH PH12016500924A patent/PH12016500924A1/en unknown
- 2016-05-19 CL CL2016001209A patent/CL2016001209A1/es unknown
-
2019
- 2019-07-05 JP JP2019125655A patent/JP6929903B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8309599B2 (en) * | 2006-09-08 | 2012-11-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| WO2013032693A2 (en) * | 2011-08-27 | 2013-03-07 | Marrone Bio Innovations, Inc. | Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom-formulations and uses |
| WO2014068443A1 (en) * | 2012-11-05 | 2014-05-08 | Pfizer Inc. | Spliceostatin analogs |
Non-Patent Citations (2)
| Title |
|---|
| ARUN K. GHOSH ET AL, "Enantioselective Syntheses of FR901464 and Spliceostatin A: Potent Inhibitors of Spliceosome", ORGANIC LETTERS , 2013, vol. 15, no. 19, pages 5088 - 5091 [Published online: 19/09/2013] * |
| SAMI OSMAN ET AL, "Structural Requirements for the Antiproliferative Activity of Pre-mRNA Splicing Inhibitor FR901464", CHEMISTRY - A EUROPEAN JOURNAL, 2011, vol. 17, no. 3, pages 895 - 904 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3071563B1 (en) | Anti-cancer agents and preparation thereof | |
| CN102234259B (zh) | 含笑内酯衍生物,其药物组合物及其制备方法和用途 | |
| US12435071B2 (en) | Bryostatin compounds and methods of preparing the same | |
| PT1767535E (pt) | Síntese de epotilonas, respectivos intermediários, análogos e suas utilizações | |
| CN101978959A (zh) | 含笑内酯及其衍生物用于治疗癌症的用途 | |
| EP3210969B1 (en) | Kcnq2-5 channel activator | |
| HK40062614A (en) | Anti-cancer agents and preparation thereof | |
| HK1227866B (en) | Anti-cancer agents and preparation thereof | |
| HK1227866A1 (en) | Anti-cancer agents and preparation thereof | |
| NZ721152B2 (en) | Anti-cancer agents and preparation thereof | |
| NZ759166B2 (en) | Anti-cancer agents and preparation thereof | |
| CA3037883A1 (en) | Anti-cancer agents and preparation thereof | |
| WO2022040788A1 (en) | Open-ring and lactone derivatives of unsaturated trihydroxy c-18 fatty acids and pharmaceutical compositions thereof having anti-cancer activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |